Today's Date: June 6, 2023
Morgan Stanley Global M&A Chair Robert Kindler to Join Paul, Weiss   •   ACC Honors Companies for Efforts to Advance Sustainability with its 2023 Sustainability Leadership Awards   •   Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)   •   WCM Champions of Change Close the Market   •   Antibiotic Overuse a Slippery Slope for STI Prevention, says AHF   •   PrideStaff Named to ClearlyRated's Best Staffing Firms for Women List   •   AVOCADO TO DONATE 1% OF REVENUE TO WOMEN'S EARTH ALLIANCE   •   PRIMO Partners Honored with Distinguished 2023 MVP Award from Multi-Unit Franchisee Magazine   •   Roth Staffing Named to ClearlyRated's Inaugural Best Staffing Firms for Women List   •   ExThera Medical Exhibits at the 2023 International Conference on Extracorporeal Organ Support in Zagreb, Croatia   •   TEXAS CHILDREN'S HOSPITAL'S DR. MARIA ELENA BOTTAZZI AWARDED THE VILCEK-GOLD AWARD FOR HUMANISM IN HEALTHCARE   •   Lost Money in Tingo Group, Inc.?   •   With New Recycling Center Fully Operational, EGGER Now Manufactures Products With Post-Consumer Recycled Wood   •   Common Future Launches New Women-led, Multiracial Co-CEO Model   •   ReNew Announces Results for the Fourth Quarter (Q4 FY23) and Fiscal 2023, both ended March 31, 2023   •   S CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against SentinelOne, Inc.   •   University of Phoenix Collaborates with Ardent Health Services to Provide Education and Tuition Reimbursement for Employees   •   Maine Public Utilities Commission Unanimously Approve Central Maine Power Multi-year Rate Plan   •   Legend Biotech Announces Submission of Supplemental Application to the U.S. FDA for Expanded Use of CARVYKTI® (ciltacabtagen   •   PrideStaff Financial Named to ClearlyRated's Best Staffing Firms for Women List
Bookmark and Share

Frost & Sullivan Lauds Micronoma with Award for Technology Innovation Leadership

SAN DIEGO , March 30 /Businesswire/ - Based on an independent team of experts’ rigorous evaluation of a broad field of nominated companies, Frost & Sullivan has selected Micronoma, the first biotech company offering early cancer detection with a microbiome-driven liquid biopsy platform, to receive this year’s Best Practices Technology Innovation Leadership Award in the North America liquid biopsy for lung cancer market.

“Driving innovation and growth is a difficult task made even harder by the strategic imperatives forcing change today, such as disruptive technologies, value chain compression, and industry convergence,” Frost & Sullivan said. “In this context, Micronoma’s recognition signifies an even greater accomplishment.”

Noting that lung cancer has one of the highest mortality rates, the panel concluded that Micronoma’s Oncobiota™ platform delivers improved diagnostic capabilities that can result in better patient outcomes and lower costs. OncobiotaLUNG was recently granted FDA Breakthrough Designation Devices status.

Frost & Sullivan, a research-based think tank focused on supporting the public and private sectors on their journey to visionary innovation, credited Micronoma for distinguishing itself compared to competitors based on performance in numerous technology and business best practice categories, including commitment to innovation, creativity and growth potential in a rapidly expanding market.

“We're extremely gratified to receive this award that recognizes the revolutionary advances Micronoma is making in early cancer detection,” Sandrine Miller-Montgomery, Micronoma CEO and co-founder, said. “Our unwavering commitment to offering a minimally invasive diagnostic option to clinicians and patients, starting with lung cancer, should be ready for clinicians this year. Our technology has vast potential to reduce the need for costly and sometimes dangerous tissue biopsies and, most importantly, help patients lead longer lives.”

To learn more about Micronoma, please go to

About Micronoma

Micronoma is the first cancer-detection company utilizing signals from circulating microbial nucleic acids in blood to diagnose cancer at an early stage with microbiome-driven liquid biopsy technology. Micronoma was founded in 2019 by leaders in microbiome research with the goal of advancing early cancer diagnostics and personalized treatment through sensitive microbiome techniques, ensuring that patients’ needs are met by their clinicians at the earliest stage for a better chance to live longer, healthier lives. The company is headquartered in San Diego, California.

STORY TAGS: United States, North America, Biotechnology, Health Technology, Health, Oncology, California, Award, Product/Service,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News